Core Viewpoint - Pediatrix Medical Group, Inc. is well-positioned for growth due to its focus on high-quality, evidence-based healthcare, achieving a year-to-date gain of 5.6% compared to a 6.4% decline in the industry average [1] Company Overview - Pediatrix Medical has a market capitalization of $1.2 billion and is based in Sunrise, FL, providing various physician services in the U.S. and Puerto Rico, including neonatal care for premature or complicated births [2] - The company's forward P/E ratio stands at 8.72, which is lower than the industry average of 13.87 [2] Financial Performance and Estimates - The Zacks Consensus Estimate for Pediatrix Medical's 2025 earnings is $1.56 per share, reflecting a 3.3% year-over-year increase, with revenue estimates at $1.9 billion [3] - The company has consistently exceeded earnings estimates over the past four quarters, with an average surprise of 24.6% [3] Growth Drivers - Growth is supported by strong same-unit revenue growth of 6.2% year-over-year in Q1 2025, improved payor mix, and increased hospital contract administrative fees [4] - Recent agreements to take over operations of multiple NICU, MFM, and OB hospitals will enhance its hospital system portfolio [5] Operating Expenses and Projections - The adjusted EBITDA projection for 2025 has been increased to a range of $220 million to $240 million, while total operating expenses decreased by 11% year-over-year to $426.3 million in Q1 2025 [6] - The model suggests operating expenses could decline by nearly 17.8% year-over-year in 2025 due to reduced practice salaries and other costs [6] Share Buyback Activity - In Q1 2025, the company repurchased common shares worth $1.6 million, with $1.3 million remaining authorized for repurchase as of March 31, 2025 [7] Investment Outlook - Pediatrix Medical is viewed as a compelling investment opportunity, supported by consistent earnings surprises, strategic acquisitions, and a focus on specialized care, making it suitable for investors seeking value and stability in the healthcare sector [10]

Group 1 - The stock of Pediatrix Medical Group (MD) closed at $13.56, reflecting a 10.7% gain over the past four weeks, with a mean price target of $17.14 indicating a potential upside of 26.4% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $2.61, where the lowest estimate is $14 (3.2% increase) and the highest is $21 (54.9% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.1% over the past month, with two estimates revised higher and no negative revisions [12] - MD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be entirely reliable, the direction it implies appears to be a good guide for potential price movement [13]

Core Viewpoint - Midland Exploration Inc. has initiated an exploration program for gold at its Caniapisc Au project, which includes geological mapping, prospecting, and an extensive soil sampling program to validate historical gold anomalies and assess the project's gold potential [1][3][5]. Exploration Program - The summer 2025 exploration program is set to begin in early June, involving geological mapping and a soil sampling program with a total of 400 soil samples planned at 200-meter spacing along lines spaced at 400 meters [3]. - A reconnaissance campaign in 2024 validated three historical till gold anomalies and conducted a geological assessment, completing a survey with five till samples [4]. Geological Findings - Results from the five till samples confirmed historical gold anomalies, with one sample returning 100 gold grains per 10 kg of till, indicating a strong anomaly [5]. - Additional samples showed 59 gold grains per 10 kg of till, with three strong gold anomalies observed in the fine fraction of the till, suggesting multiple distinct gold sources in the area [5]. Prospecting Results - Prospecting work in 2024 identified boulder fields and outcrops, with 47 out of 55 grab samples collected near historical gold anomalous tills yielding anomalous gold values ranging from 0.10 to 0.75 g/t Au [6]. - The mineralization is primarily associated with sedimentary host rocks, with pyrite and silica alteration being prevalent [6]. Project Location and Geological Context - The Caniapisc Au project is located within the Ashuanipi Subprovince, characterized by a volcanosedimentary belt, and is strategically positioned north of historical mineralization showings [7]. - Historical exploration has indicated the potential for various mineralization types in the surrounding area, including volcanogenic and porphyry deposits [7]. Quality Control and Analysis - Rock samples from the project were analyzed using industry-standard methods, ensuring quality control through the use of standards and blanks [8][9].

Core Viewpoint - Pediatrix Medical Group, Inc. reported strong first-quarter 2025 results, leading to an 11.5% increase in shares, driven by same-unit revenue growth, improved payor mix, and a decline in overall expenses, although higher clinical compensation costs partially offset these gains [1][2]. Financial Performance - Adjusted earnings per share (EPS) for Q1 2025 were 33 cents, exceeding the Zacks Consensus Estimate by 32% and showing a 65% year-over-year increase [2]. - Net revenues totaled $458.4 million, a decline of 7.4% year over year, but still beating the consensus mark by 0.9% [2]. - Same-unit revenues improved by 6.2% year over year, surpassing estimates, with patient volume contributing a 1.6% increase [3]. - Total operating expenses decreased by 11% year over year to $426.3 million, driven by lower practice salaries and benefits, which fell 8.7% to $337 million [4]. - Net income reached $20.7 million, a significant increase from $4 million in the prior-year quarter, while adjusted EBITDA rose 32.3% to $49.2 million [5]. Cash and Debt Position - As of March 31, 2025, cash and cash equivalents were $99 million, down from $229.9 million at the end of 2024, with total assets declining to $2 billion [6]. - Total debt, including finance leases, was $612.6 million, a slight decrease from $617.7 million at the end of 2024 [6]. Shareholder Equity and Repurchase - Total shareholders' equity increased to $789.2 million from $764.9 million at the end of 2024 [7]. - The company repurchased common shares worth $1.6 million in Q1 2025, with a remaining capacity of $1.3 million under its $500 million repurchase program [8]. Future Outlook - Management revised the 2025 adjusted EBITDA projection to between $220 million and $240 million, up from the previous range of $215 million to $235 million [9]. - Estimated net income for 2025 is projected to be between $106.21 million and $120.81 million, with interest expenses forecasted at $36.87 million [10].

Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Company Participants Mark Ordan - CEO & Chair of the Board of DirectorsKasandra Rossi - EVP, CFO & TreasurerA.J. Rice - Managing DirectorJack Slevin - VP - Healthcare Services Equity Research Conference Call Participants Pito Chickering - Analyst Operator Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform ...

Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward looking statements are based on assumptions and assessments made by Pediatrics' management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other fa ...

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Financial Performance - Net revenue for the three months ended March 31, 2025, was $458.4 million, a decrease of $36.7 million, or 7.4%, compared to $495.1 million for the same period in 2024[73] - Same-unit net revenue increased by $26.1 million, or 6.2%, driven by a $19.4 million increase from net reimbursement-related factors and a $6.7 million increase related to patient service volumes[73] - Adjusted EBITDA for the three months ended March 31, 2025, was $49.2 million, compared to $37.2 million for the same period in 2024, reflecting an increase of $11.9 million[72] - Adjusted EPS for the three months ended March 31, 2025, was $0.33, compared to $0.20 for the same period in 2024, representing a 65% increase[72] - Income from operations increased by $16.2 million, or 102.0%, to $32.1 million for the three months ended March 31, 2025, compared to $15.9 million for the same period in 2024[79] - Operating margin improved to 8.4% for the three months ended March 31, 2025, up from 4.9% for the same period in 2024[80] - Net income rose to $20.7 million for the three months ended March 31, 2025, compared to $4.0 million for the same period in 2024[83] - Adjusted EBITDA increased to $49.2 million for the three months ended March 31, 2025, from $37.2 million for the same period in 2024[83] Expenses - Practice salaries and benefits decreased by $32.1 million, or 8.7%, to $337.0 million for the three months ended March 31, 2025, compared to $369.1 million for the same period in 2024[74] - General and administrative expenses were $58.6 million for the three months ended March 31, 2025, a decrease of $1.6 million compared to $60.2 million for the same period in 2024[76] - Transformational and restructuring related expenses were $6.6 million for the three months ended March 31, 2025, compared to $8.5 million for the same period in 2024[78] - Total non-operating expenses decreased to $4.0 million for the three months ended March 31, 2025, from $8.1 million for the same period in 2024[81] Cash Flow and Liquidity - Cash used in operating activities decreased to $116.1 million for the three months ended March 31, 2025, from $122.6 million for the same period in 2024[87] - As of March 31, 2025, the company had $99.0 million in cash and cash equivalents, down from $229.9 million at December 31, 2024[85] - The outstanding principal balance on the Amended Credit Agreement was $210.9 million as of March 31, 2025[96] - A 1% change in interest rates would impact income before taxes by approximately $2.1 million per year based on the outstanding balance of the Amended Credit Agreement[104] Operational Metrics - The percentage of patient service revenue reimbursed under government-sponsored healthcare programs decreased during the three months ended March 31, 2025, compared to the same period in 2024[61] - Days sales outstanding (DSO) improved to 47.6 days at March 31, 2025, down from 52.2 days at March 31, 2024[89] Strategic Changes - The company completed the exit of its pediatric office-based practices as of December 31, 2024, to focus on hospital-based and maternal-fetal medicine services[62] - The company anticipates potential impacts from changes in government-sponsored healthcare programs and the expiration of COVID-19 related emergency declarations[67]

• Net revenue of $458 million; • Net income of $21 million; and • Adjusted EBITDA of $49 million. Operating Results– Three Months Ended March 31, 2025 Pediatrix's net revenue for the three months ended March 31, 2025 was $458.4 million, compared to $495.1 million for the prior-year period. This decrease reflects the impact of non-same unit activity, primarily practice dispositions, partially offset by growth in same-unit net revenue of 6.2 percent. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice Pres ...

Physician services provider Pediatrix Medical Group, Inc. (MD) is set to report its first-quarter 2025 results on May 6, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 25 cents per share and $454.5 million, respectively. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year- ...